Loading
Life sciences · Journal article
Microbiologyopen · August 31, 2026
Raises a question worth testing. It does not answer one.
This is a descriptive bibliometric mapping of 1,746 peer-reviewed publications (2000–2025) on molecular diagnostics for WHO priority bacterial pathogens, identifying research clustering around MRSA, tuberculosis, and carbapenem-resistant organisms, and documenting a shift from pathogen detection toward resistance-centered translational research. The analysis frames diagnostic innovation priorities but does not evaluate the clinical efficacy, accuracy, or impact of any diagnostic platform or workflow.
Bibliometric mapping study with systematic literature retrieval. Peer-reviewed publications (articles and reviews) in Scopus addressing molecular diagnostics, resistance markers, and/or antimicrobial resistance for WHO priority pathogens.. n = 1,746. Global; publication output led by China and the United States..
1746 Scopus-indexed publications retrieved after PRISMA-adapted screening over 2000–2025 timeframe Literature expansion accelerated markedly after 2018, with China and the United States leading publication output MRSA, Mycobacterium tuberculosis, Enterococcus faecium, and Enterobacterales-carbapenemase axis identified as principal thematic cores
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This mapping identifies research priorities and platform evolution relevant to diagnostic stewardship and surveillance policy, but does not directly inform clinical decision-making or evidence for a specific diagnostic test's performance or clinical utility.
A bibliometric mapping study that describes publication trends and thematic evolution in molecular diagnostics for WHO priority pathogens, raising questions about diagnostic priorities and workflow integration rather than testing a clinical hypothesis with empirical outcome data.
As stated by the source record.
Quoted from the source exactly as published.
This mapping identifies research priorities and platform evolution relevant to diagnostic stewardship and surveillance policy, but does not directly inform clinical decision-making or evidence for a specific diagnostic test's performance or clinical utility.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Antimicrobial resistance (AMR) constrains effective treatment and carries implications for infection control, surveillance, and public health. The World Health Organization (WHO) priority bacterial pathogen framework has intensified the need for diagnostic innovation by redefining research priorities around organisms combining high disease burden with complex resistance profiles. Molecular diagnostics have accordingly moved beyond culture-based workflows, integrating rapid pathogen identification, resistance-marker detection, genomic surveillance, and clinical decision support. The present study conducted a bibliometric mapping of the literature on WHO priority pathogens. Rather than addressing resistance at a general level or a single pathogen or technology, it integrates priority pathogens, molecular platforms, and resistance markers within a single framework, tracing their joint thematic and temporal evolution along an explicit pathogen-platform-marker axis. Scopus-indexed articles and reviews (2000-2025) were retrieved, yielding 1746 publications after screening adapted from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Analyses used Bibliometrix/Biblioshiny, R, and VOSviewer. The literature expanded markedly after 2018, led by China and the United States. Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium tuberculosis, Enterococcus faecium, and the Enterobacterales-carbapenemase axis constituted the principal thematic cores, whereas conventional polymerase chain reaction (PCR)/nucleic acid amplification testing (NAAT) and whole-genome sequencing were the dominant platforms. Overall, the field has evolved from pathogen detection into an AMR-centered translational domain encompassing resistance prediction, genomic epidemiology, surveillance, and clinical decision support. Diagnostic development, stewardship, and surveillance depend on hybrid workflows coupling rapid marker-targeted assays with genome-based characterization, delivering actionable resistance within clinically meaningful timeframes, and extending coverage to underrepresented pathogens and platforms.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.